Why TG Therapeutics, Inc.’s (TGTX) Stock Is Up 5.69%
As of Wednesday, September 16, TG Therapeutics, Inc.’s TGTX share price has surged by 5.69%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
Commentary & Analysis
Why TG Therapeutics, Inc.’s (TGTX) Stock Is Up 9.06%
As of Friday, August 21, TG Therapeutics, Inc.’s TGTX share price has surged by 9.06%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why TG Therapeutics, Inc.’s (TGTX) Stock Is Up 11.53%
As of Friday, August 21, TG Therapeutics, Inc.’s TGTX share price has surged by 11.53%, which has investors questioning if this is right time to sell.Jenna Brashear
Which Is a Better Investment, TG Therapeutics, Inc. or Xencor, Inc. Stock?
Learn more about whether TG Therapeutics, Inc. or Xencor, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
Why TG Therapeutics, Inc.’s (TGTX) Stock Is Down 8.53%
As of Monday, August 03, TG Therapeutics, Inc.’s TGTX share price has dipped by 8.53%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | TGTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $7,854.1 | $242.6 | 75% |
|
| Shares Out (Mil) | 157.3 | 54.0 | 72% |
|
| Institutional Ownership | 94.8% | 93.1% | 66% |
|
| Float (Mil) | 135.2 | 41.4 | 66% |
|
| Beta | 1.66 | 0.95 | 86% |
|
| Avg Daily Volume (000s) | 1,755 | 633 | 79% |
|
| Price Change (52-week) |
54.9% | 50.0% | 86% |
|
| Growth | TGTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 398.6% | 12.5% | 100% |
|
| Net Income (5yr) | 29.2% | (10.1%) | 84% |
|
| EPS (5yr) | 25.7% | 15.8% | 76 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.9%) | (15.7%) | 42% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 5 | |
| Current EPS | $0.258 | $0.950 | $2.708 | |
| Month Ago EPS | $0.328 | $0.950 | $2.965 | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | $0.426 | $1.584 | $3.217 | |
| Year/Year Chg | 416.0% | (65.7%) | 19.3% | |
| Financials | TGTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $800 | $37 | 47% |
|
| Net Income (TTM) (Mil) | $442 | ($44) | 77% |
|
| EPS (TTM) | $3.098 | ($1.600) | 79% |
|
| Operating Cash Flow (TTM) (Mil) | $18 | ($34) | 40% |
|
| Net Cash Flow (TTM) (Mil) | $354 | $2 | 88% |
|
| Long-Term Debt (Q1) (Mil) | $753 | $4 | 63% |
|
| Enterprise Value (Q1) (Mil) | $8,269 | $177 | 71% |
|
| Valuation | TGTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 13.00 | 2.33 | 93% |
|
| P/E | 20.0 | 19.6 | 54% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.8 | 1.0 | 38% |
|
| Ratios | TGTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 82.4% | 67.3% | 90% |
|
| Net Margin | 55.2% | (74.8%) | 97% |
|
| ROA | 37.7% | (47.6%) | 99% |
|
| ROE | 100.3% | (54.9%) | 96% |
|
| Liabilities to Assets | 63.2% | 29.3% | 58% |
|
| F-Score | 5 | 3 | 50% |
|
TG Therapeutics, Inc. did not pass any screens on 10/9/2026.
